Liraglutide and Semaglutide Market Report 2025

This Liraglutide and Semaglutide market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The liraglutide and semaglutide market size has grown rapidly in recent years. It will grow from $15.19 billion in 2024 to $16.98 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to the increasing prevalence of diabetes, growing incidence of obesity-related diseases, growth in the number of clinical trials, growing investment in diabetes research and development, and rising demand for convenient treatment options.

The liraglutide and semaglutide market size is expected to see rapid growth in the next few years. It will grow to $26.24 billion in 2029 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to rising adoption of GLP-1 receptor agonists, increasing healthcare expenditure, expansion of pharmaceutical company product portfolios, rising disposable incomes, rising geriatric population susceptible to diabetes. Major trends in the forecast period include the integration of digital health platforms, implementation of personalized dosing strategies, advancements in drug delivery technologies, development of biosimilar versions, and integration of artificial intelligence in treatment decision-making.

The growing number of diabetic patients is expected to drive the growth of the liraglutide and semaglutide markets in the future. Diabetes is a chronic condition marked by elevated blood sugar levels due to insulin resistance and insufficient insulin production. The increasing prevalence of diabetes can be attributed to factors such as sedentary lifestyles, poor dietary habits, and genetic predispositions. Liraglutide and semaglutide play a crucial role in managing diabetes by helping control blood glucose levels and reducing the risk of related complications. For example, in June 2024, the National Health Service (NHS), a UK-based government department, reported that in 2023, over half a million additional individuals in England were identified as being at risk of developing type 2 diabetes. This brought the total number of people with pre-diabetes, or non-diabetic hyperglycemia, registered with a GP to 3,615,330, marking a nearly 20% increase from 2022, when the number was 3,065,825. Thus, the rising number of diabetic patients is driving the growth of the liraglutide and semaglutide markets.

Leading companies in the liraglutide and semaglutide markets are creating anti-diabetic biosimilar drugs to improve glucose management and lower cardiovascular risks for patients. These biosimilars are affordable, nearly identical replicas of original diabetes biologics, designed to offer the same health benefits as the original medications. For example, in January 2024, Glenmark Pharmaceuticals Ltd., based in India, introduced a biosimilar of the widely used anti-diabetic drug Liraglutide in India. This new biosimilar, aimed at enhancing glycemic control for adults with type 2 diabetes mellitus, significantly reduces daily therapy costs by about 70%, with a standard 1.2 mg dose priced around INR 100, making treatment more accessible nationwide. Prescription is required for purchase.

In October 2023, Biocon Limited, an Indian biopharmaceutical firm specializing in biosimilar diabetes medications such as liraglutide (Victoza) and semaglutide (Ozempic), formed a partnership with Juno Pharmaceuticals. This collaboration focuses on bringing Liraglutide, a complex drug-device combination for Type 2 diabetes and obesity treatment, to market. The partnership aims to secure regulatory approval, streamline manufacturing, and enhance supply, ultimately improving healthcare access and affordability through innovative solutions. Juno Pharmaceuticals, based in Canada, develops high-value generic medications, complex formulations, and biosimilars.

Major companies operating in the liraglutide and semaglutide market are Pfizer Inc., Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Sun Pharmaceutical Industries Ltd., Sumitomo Pharma Co. Ltd., Shionogi & Co. Ltd., Cadila Pharmaceuticals, Kyowa Kirin Co. Ltd., Dr. Reddy's Laboratories Ltd., Biocon, Glenmark Pharmaceuticals Ltd., Bachem, Zealand Pharma, Shenzhen JYMed Technology Co. Ltd., Incepta Pharmaceuticals Ltd.

North America was the largest region in the liraglutide and semaglutide market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide and semaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liraglutide and semaglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liraglutide and semaglutide are medications classified as glucagon-like peptide-1 (GLP-1) receptor agonists. They are primarily used to manage type 2 diabetes mellitus and help improve glycemic control in adults with this condition. These injectable medications are generally prescribed when other diabetes or obesity treatments have proven insufficient. They are often included in a comprehensive treatment plan that may also involve diet, exercise, and additional medications as needed.

Liraglutide and semaglutide are available in two main forms pills and liquids. Pills are solid-form medications usually taken orally to treat conditions such as type 2 diabetes mellitus and obesity. The medications can be administered in various ways, including parenteral and oral methods, depending on the application. They are distributed through multiple channels such as hospital pharmacies, retail pharmacies, and online pharmacies.

The liraglutide and semaglutide market research report is one of a series of new reports that provides liraglutide and semaglutide market statistics, including liraglutide and semaglutide industry global market size, regional shares, competitors with a liraglutide and semaglutide market share, detailed liraglutide and semaglutide market segments, market trends and opportunities, and any further data you may need to thrive in the liraglutide and semaglutide industry. This liraglutide and semaglutide market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The liraglutide and semaglutide markets consist of sales of medicines such as Victoza, saxenda, ozempic, and rybelsus. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.